Predicting the propofol effect-site concentration that causes deep anesthesia
Official title: Prediction of Propofol Effect-Site Concentration Associated With Deep Anesthesia During Induction of General Anesthesia Based on Electroencephalographic Features: a Prospective Observational Study
Run by Ciusss de L'Est de l'Île de Montréal · NCT06346158 · Data updated 2026-11-12
We will test whether pre‑op EEG patterns, brief cognitive tests, and patient characteristics can predict the propofol level needed to reach deep anesthesia in adults having general anesthesia.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 110 (estimated) |
| Sponsor | Ciusss de L'Est de l'Île de Montréal Academic / other |
| Locations | 1 site (Montreal, Quebec) |
| Status | Recruiting |
| Started | April 7, 2025 |
| Main results expected | January 2027 |
| Study ends | January 2027 |
| Registry record updated | January 16, 2026 |
| Trial ID | NCT06346158 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults scheduled for any type of surgery under general anesthesia who can communicate in French or English and meet the study's medical inclusion criteria are ideal candidates.
✕Probably not a fit
Patients who are excluded by the protocol—such as those with BMI ≥ 35 kg/m2, known propofol contraindications, those requiring rapid sequence induction, anticipated difficult airway/ventilation, or who cannot communicate in French or English—are unlikely to benefit from the study's predictions.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational, single‑center study records awake high‑density EEG and preoperative cognitive performance in adults scheduled for surgery under general anesthesia, then induces anesthesia with a continuous propofol infusion using target‑controlled methods. Investigators will record the effect‑site concentration (Ce) at which deep anesthesia is observed and analyze interindividual variability. Demographic, cognitive, and EEG features will be related to the Ce for deep anesthesia and used to train and validate machine‑learning models to predict individual sensitivity. The goal is to identify EEG or cognitive signatures that mark increased vulnerability to propofol and to improve individualized dosing strategies.
Why it matters
Potential benefit: If successful, this approach could enable more personalized propofol dosing to reduce risks of over‑ or under‑sedation and help identify patients with vulnerable brain phenotypes.
How similar studies have gone: Previous work has shown correlations between age, cognitive status, EEG features, and propofol sensitivity, but comprehensive predictive models combining EEG, cognition, and demographics remain limited and are still being developed.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Scheduled for any kind of surgery under general anesthesia. * Adults Exclusion Criteria: * Inability to communicate in French or English, * Known allergy or intolerance or other medical condition that precludes the use of prescribed general anesthesia protocol for this study, * Patients requiring rapid sequence induction, * Anticipated or known difficult intubation patient, * Anticipated or known difficult ventilation patient, * Body mass index ≥ 35 kg.m-2.
Where it's running
-
Hopital Maisonneuve-Rosemont
Montreal, Quebec, Canada Recruiting
Study contacts
- Principal investigator: Louis Morisson, MD, MSc — CIUSSS de l'Est de l'Ile de Montréal
- Study coordinator: Louis Morisson, MD, MSc
- Email: louis.morisson@umontreal.ca
- Phone: 514-252-3400
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Theta-Burst Transcranial Magnetic Stimulation for Treatment-Resistant Auditory Hallucinations
This study tests whether theta-burst transcranial magnetic stimulation can lessen persistent auditory verbal hallucinations in adults with schizophrenia-spectrum or psychotic disorders who have not responded to antipsychotic meds.
-
Higher-dose UM171 to improve cord blood stem cell transplants
This will try a higher lab dose of UM171 to expand umbilical cord blood stem cells for adults with high-risk leukemia or myelodysplasia who lack a suitable donor to see if they recover blood counts faster and have fewer complications after transplant.
-
Home-based transcranial direct current stimulation (tDCS) for depression in borderline personality disorder
This project will see if 14 home-based tDCS sessions, compared with sham, can reduce depressive symptoms in adults with borderline personality disorder and moderate-to-severe depression.
-
Dexmedetomidine infusion to reduce intraoperative remifentanil use during laparoscopic abdominal surgery
This trial tests whether giving a dexmedetomidine infusion during laparoscopic abdominal surgery can lower the amount of remifentanil needed during the operation.
-
Quality of life during the transition to home versus in-center dialysis
This project will see if people with advanced CKD who start home dialysis have better quality of life and less frailty over the first year than those who start in-center hemodialysis.
-
New treatment approach for obsessive-compulsive disorder
This study is testing whether a new therapy called Inference-based Cognitive Behavioral Therapy can help people with obsessive-compulsive disorder feel better compared to the usual treatment they’ve already tried.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.